Cargando…

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVES: Linaclotide is a guanylate cyclase-C agonist approved in the United States, Canada, and Mexico at a once-daily 145-μg dose for the treatment of chronic idiopathic constipation (CIC); a once-daily 72-μg dose for CIC recently received FDA approval. The trial objective was to evaluate the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoenfeld, Philip, Lacy, Brian E, Chey, William D, Lembo, Anthony J, Kurtz, Caroline B, Reasner, David S, Bochenek, Wieslaw, Tripp, Kenneth, Currie, Mark G, Fox, Susan M, Blakesley, Rick E, O’Dea, Christopher R, Omniewski, Nicholas D, Hall, Michael L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Functional GI Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770595/ https://www.ncbi.nlm.nih.gov/pubmed/29091082 http://dx.doi.org/10.1038/ajg.2017.230

Ejemplares similares

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
por: Lacy, Brian E, et al.
Publicado: (2017)

A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation
por: Chey, William D, et al.
Publicado: (2011)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study
por: Brenner, Darren M., et al.
Publicado: (2020)

Prucalopride Improves Bowel Function and Colonic Transit Time in Patients With Chronic Constipation: An Integrated Analysis
por: Emmanuel, Anton, et al.
Publicado: (2014)

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
por: Jamal, M Mazen, et al.
Publicado: (2015)

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
por: Miner Jr, Philip B, et al.
Publicado: (2017)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation
por: Yiannakou, Yan, et al.
Publicado: (2015)

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
por: Chey, William D., et al.
Publicado: (2021)

Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus
por: Rezaie, Ali, et al.
Publicado: (2017)

Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome
por: Marquis, P, et al.
Publicado: (2014)

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial
por: Lacy, Brian E., et al.
Publicado: (2015)

Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea
por: Pattni, Sanjeev S, et al.
Publicado: (2012)

The Epidemiology of Irritable Bowel Syndrome in the US Military: Findings from the Millennium Cohort Study
por: Riddle, Mark S, et al.
Publicado: (2016)

Association Between the Location of Diverticular Disease and the Irritable Bowel Syndrome: A Multicenter Study in Japan
por: Yamada, Eiji, et al.
Publicado: (2014)

The Effect of High-Fat Diet-Induced Pathophysiological Changes in the Gut on Obesity: What Should be the Ideal Treatment?
por: Y Lee, Chooi
Publicado: (2013)

Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable Bowel Syndrome Revealed by MRI
por: Lam, Ching, et al.
Publicado: (2017)

Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome
por: Sayuk, Gregory S, et al.
Publicado: (2017)

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
por: Brenner, Darren M., et al.
Publicado: (2023)

Constipation-related direct medical costs in 16 887 patients newly diagnosed with chronic constipation
por: Dik, Vincent K., et al.
Publicado: (2014)

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C
por: Lacy, B E, et al.
Publicado: (2014)

Functional bowel symptoms, fibromyalgia and fatigue: A food-induced triad?
por: Berstad, Arnold, et al.
Publicado: (2012)

Diagnostic pitfalls in functional neurological disorders
por: Pimentel, Lucio Huebra, et al.
Publicado: (2022)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

Linaclotide induces secretion of cGMP from mouse colonic epithelium
por: Tchernychev, Boris, et al.
Publicado: (2013)

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials
por: Chang, L, et al.
Publicado: (2014)

Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults
por: Parker, Colleen H., et al.
Publicado: (2013)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study
por: Taylor, Douglas C.A., et al.
Publicado: (2019)

Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide
por: Chandar, Apoorva Krishna
Publicado: (2017)

Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
por: Rey, Enrique, et al.
Publicado: (2017)

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States
por: Nag, Arpita, et al.
Publicado: (2020)

The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review
por: Baaleman, Desiree F., et al.
Publicado: (2021)

Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt
por: Nakae, Hirohiko, et al.
Publicado: (2016)

Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis
por: Appleby, Richard N, et al.
Publicado: (2017)

Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia
por: Igarashi, Muneki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bgsu8o10d6ablukrck1cm25och